Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 545Lung Neoplasms 240Small Cell Lung Carcinoma 106Mesothelioma, Malignant 57Adenocarcinoma of Lung 41Mesothelioma 35Neoplasms 27Neoplasm Metastasis 25Colorectal Neoplasms 22Carcinoma 17Squamous Cell Carcinoma of Head and Neck 15Ovarian Neoplasms 15Adenocarcinoma, Bronchiolo-Alveolar 14Parkinson Disease 4, Autosomal Dominant Lewy Body 13Stomach Neoplasms 12Pancreatic Neoplasms 12Non-Squamous Non-Small Cell Lung Cancer 12Head and Neck Neoplasms 12Pleural Effusion, Malignant 8Melanoma 8Breast Neoplasms 8Sarcoma 7Extensive Stage Small Cell Lung Cancer 7Triple Negative Breast Neoplasms 6Thymoma 6Solitary Fibrous Tumor, Pleural 6NSCLC 6Endometrial Neoplasms 6Drug-Related Side Effects and Adverse Reactions 6Colonic Neoplasms 6

Interventions

pembrolizumab 1patritumab deruxtecan 1Platinum Compounds 1Pemetrexed 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nonsquamous Non-small Cell Lung Cancer × Cisplatin × Thoracic × Clear all
NCT04750083 2021-02-11

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Taizhou Hanzhong biomedical co. LTD

Phase 2/3 Unknown
700 enrolled
Thoracic

Nonsquamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡